AGARWALEYE500.20

Dr. Agarwal's Health Care Ltd.

· Pharma & Health
₹ CrorePeersAKUMSADVENZYMESALIVUSAARTIPHARMAARTIDRUGSAPLLTDCORONAHCGMcap ₹15,846 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Inventory Days (DIO)24,829.2839,908.0839,908.08
Receivable Days (DSO)26.3628.2428.24
Payable Days (DPO)47,341.7463,348.7256,164.85
Cash Conversion Cycle (days)-22,486.10-23,412.40-16,228.53
Working Capital Turnover5.4118.6619.79
Asset Turnover0.470.530.53
Cash Conversion (CFO/Net Income)3.273.093.09
CFO/EBITDA0.790.910.91
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.